Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Catheter Precision ( (VTAK) ) just unveiled an update.
On May 19, 2025, Catheter Precision, Inc. entered into an At Market Offering Agreement with Ladenburg Thalmann & Co. Inc. to potentially sell up to $1.3 million of its common stock. The proceeds from any sales will be used to fund operations and working capital. Ladenburg will sell shares based on the company’s instructions, adhering to legal and exchange rules. The agreement can be terminated by either party with notice, and Ladenburg will receive a 3% commission on sales.
Spark’s Take on VTAK Stock
According to Spark, TipRanks’ AI Analyst, VTAK is a Underperform.
VTAK faces significant financial challenges, with declining revenue and ongoing losses impacting its financial health. Technical indicators suggest bearish trends, and the negative P/E ratio reflects market concerns about profitability. These factors result in a low overall stock score.
To see Spark’s full report on VTAK stock, click here.
More about Catheter Precision
Average Trading Volume: 199,902
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.2M
Find detailed analytics on VTAK stock on TipRanks’ Stock Analysis page.